PT  - JOURNAL ARTICLE
AU  - Moghadas, Seyed M.
AU  - Sah, Pratha
AU  - Fitzpatrick, Meagan C.
AU  - Shoukat, Affan
AU  - Pandey, Abhishek
AU  - Vilches, Thomas N.
AU  - Singer, Burton H.
AU  - Schneider, Eric C.
AU  - Galvani, Alison P.
TI  - COVID-19 deaths and hospitalizations averted by rapid vaccination rollout in the United States
AID  - 10.1101/2021.07.07.21260156
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.07.21260156
4099  - http://medrxiv.org/content/early/2021/07/08/2021.07.07.21260156.short
4100  - http://medrxiv.org/content/early/2021/07/08/2021.07.07.21260156.full
AB  - Importance Randomized clinical trials have shown that the COVID-19 vaccines currently approved in the US are highly efficacious. However, more evidence is needed to understand the population-level impact of the US vaccination rollout in the face of the changing landscape of COVID-19 pandemic in the US, including variants with higher transmissibility and immune escape.Objective To quantify the population-level impact of the US vaccination campaign in averting cases, hospitalizations and deaths from December 12, 2020 to June 28, 2021.Design Age-stratified agent-based model which included transmission dynamics of the Alpha, Gamma and Delta variants in addition to the original Wuhan-1 variant.Setting Our model was calibrated to COVID-19 outbreak and vaccine rollout in the US. Model predictions were made at the country level.Participants Simulated age-stratified population representing US demographics.Main Outcomes and Measures Cases, hospitalizations and deaths averted by vaccination against COVID-19 in the US, compared to the counterfactuals of no vaccination and vaccination administered at half the actual pace.Results The swift vaccine rollout in the US curbed a potential resurgence of cases in April 2021, which would have been otherwise fuelled by the Alpha variant. Compared to the scenario without vaccines, we estimated that the actual vaccination program averted more than 26 million cases, 1.2 million hospitalizations and saved 279,000 lives. A vaccination campaign with half the actual rollout rate would have led to an additional 460,000 hospitalizations and 121,000 deaths.Conclusions and Relevance The COVID-19 vaccination campaign in the US has had an extraordinary impact on reducing disease burden despite the emergence of highly transmissible variants. These findings highlight that the pace of vaccination was essential for mitigating COVID-19 in the US, and underscore the urgent need to close the vaccine coverage gaps in communities across the country.Question How effective was the United States (US) vaccination campaign in suppressing COVID-19 burden?Findings The vaccination campaign was highly effective in curbing the COVID-19 outbreak in the US. We estimated that the vaccine rollout saved over 275,000 lives and averted 1.2 million hospitalizations.Meaning The swift vaccine rollout in the US averted a remarkable number of cases, hospitalizations and deaths despite the emergence of highly transmissible variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Commonwealth Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was not required as all data is publicly available.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe simulation codes are available at: https://github.com/thomasvilches/multiple_strains https://github.com/thomasvilches/multiple_strains